A meta-analysis by Filippatos et al. reported that, since 2009, headaches have been documented across several GLP-1 RAs trials.26They are generally mild, nondisabling, and most frequently occur within the first 26 weeks of treatment. The gene discussed is GLP1R; the disease is Headache.